Absci Corporation (ABSI)
(Delayed Data from NSDQ)
$4.53 USD
-0.18 (-3.82%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $4.52 -0.01 (-0.22%) 6:22 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ABSI 4.53 -0.18(-3.82%)
Will ABSI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ABSI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABSI
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
Absci Corporation (ABSI) Surges 10.0%: Is This an Indication of Further Gains?
ABSI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Centene (CNC) Stock Outpacing Its Medical Peers This Year?
Is Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year?
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
Other News for ABSI
Moderna and OpenAI in pact to fast-track drug development
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Video: Tuesday's ETF Movers: ARKG, PICK
All 7 AI Category Portfolios Continued To Decline This Week
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024